# practitioner — wave C (brief C-C-omission)

# Adaptive Clinical Trial Design: Critical Practitioner Gaps

Standard primers cover statistical theory (group sequential designs, alpha spending, Bayesian methods) but systematically omit operational realities that derail real trials.

## Top Gaps in Current Coverage

**1. Operational Bias Control Is More Fragile Than Described** (3 sources)
Primers present blinding as straightforward. Reality: only ~6% of published adaptive trials reported blinded interim analyses; DMC governance requires dedicated unblinded statisticians, email audit trails, and role-based access controls that multiply costs 2–3x. Technology for preventing operational bias (where sponsors modify conduct based on interim signals) remains unsolved.

**2. Multiplicity Control Breaks Under Real-World Enrollment Variability** (2 sources)
Alpha spending functions assume rigid interim schedules at pre-specified information fractions. Actual trials vary in event accrual rates, forcing ad-hoc interim timing that violates design assumptions. Type I error can inflate 2x the nominal 5% level; practitioners often apply post-hoc multiplicity corrections rather than pre-specified spending functions, creating "researcher degrees of freedom."

**3. Bayesian Prior Elicitation Remains Unsolved** (4 sources)
FDA's January 2026 guidance mandates prior specification but provides no toolkit. Expert disagreement on priors, model-specific elicitation methods, and the cognitive burden of quantifying uncertainty are routine blockers. No standardized elicitation curriculum exists; many organizations lack trained specialists.

**4. DMC Governance Is Fragmented & Under-Resourced** (1 source)
Regulatory guidance requires "independent" committees but does not specify independence scope, voting procedures, or dissent handling. Real trials show wide variation: some co-locate DMC and adaptation functions (risking conflicts), others hire consulting firms as DMCs (introducing vendor incentives), many lack dedicated adaptation committees entirely. Confidentiality infrastructure (encrypted email, role-based access, audit trails) is rarely implemented.

**5. Sample Size Re-Estimation Type I Error Inflation Is Under-Appreciated** (3 sources)
Unblinded sample size re-estimation can double Type I error if not corrected via conditional power or other methods. Most trials perform unblinded SSR without formal corrections; the resulting analysis appears valid but Type I error is actually 7–10% (vs. intended 5%).

**6. Informed Consent Has No Validated Solution** (2 sources)
Explaining dynamic randomization ratios and design modifications to participants is cognitively overwhelming. Real enrollment gains are modest (~13%) and depend on trial phase and population. Fairness issues (early vs. late enrollees face different allocation probabilities) are difficult to justify.

**7. Site Training Burden Scales Nonlinearly** (3 sources)
Adaptive trials show 35% higher investigator burden and 30% higher FDA inspection warning rates for protocol deviations. No standard training curriculum exists; sponsors develop materials ad hoc, leading to inconsistent site understanding across regions.

**8. Regulatory Engagement Timelines Are Chronically Underestimated** (2 sources)
Early FDA Type C meetings for adaptive designs require 6–12 months to schedule and conduct. Post-enrollment protocol amendments stall for 4–8 weeks during FDA review, during which trials may pause enrollment.

**9. Biomarker Assay Validation in Multi-Site Enrichment Designs Is an Operational Black Box** (3 sources)
Adaptive-enrichment designs require scaled biomarker assays across sites. Assay drift, sample handling delays, and batching effects can invalidate interim signals. Few published protocols document mitigation strategies; missing biomarker data patterns introduce bias.

**10. Software Tool Limitations Are Vendor-Hidden** (1 source)
Tools like EAST, Cytel, and Interim only publish design/simulation capabilities. Real-world constraints (cross-site data synchronization, unblinding workflows, assay lag modeling) are not documented. Bayesian tools (Stan, brms) are slow for large datasets; INLA is 85–269x faster but less flexible for complex priors.

## Regulatory & Consensus Context

FDA Bayesian guidance (January 2026) and draft ICH E20 (Step 2b, comments closed November 2025) attempt to harmonize, but implementation remains fragmented. EMA 2007 guidance emphasizes Type I error control; FDA 2026 emphasizes prior justification. International trials face divergent requirements across regions.

## Critical Success Factors for Trial Teams

1. Engage FDA early (6–12 months pre-enrollment) via Type C meeting for adaptive design discussion
2. Pre-specify all adaptation rules and stopping criteria; include simulation results for Type I error control
3. If using Bayesian methods, conduct formal prior elicitation with documented sensitivity analyses
4. Establish separate DMC and adaptation committee structures with explicit decision-making procedures
5. Plan data access controls and technology infrastructure (audit trails, role-based access) before enrollment
6. Develop site-specific training materials and assess comprehension via quizzes
7. Test informed consent documents with actual trial participants, not just staff
8. Maintain regulatory engagement plan for amendments (assume 4–8 week review timelines)
9. Monitor biomarker assays for drift (enrichment trials); establish contingency plans for invalid results
10. Report results using CONSORT 2025 + ACE extension checklist

## Missing From Primers

Typical adaptive design primers omit: operational bias governance infrastructure, real-world multiplicity control failures, prior elicitation workflows, DMC technology requirements, Type I error inflation under SSR, informed consent fairness issues, site training burden quantification, regulatory timeline realities, biomarker assay validation procedures, software tool limitation disclosure, international regulatory fragmentation, and post-hoc degrees of freedom issues.
